Hoosier Cancer Research Network’s LUN14-179 study was accepted as an oral presentation to the American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, 2018, at the McCormick Place in Chicago.

Study co-investigator Greg Durm, MD, of the Indiana University Melvin and Bren Simon Cancer Center, will present results from the phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer during the Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers oral abstract session on Monday, June 4, at 8 a.m. in Hall B1. See abstract.

If you go:

• Session Type: Oral Abstract Session
• Date and Time: Monday, June 4, 8:00 to 8:12 AM
• Location: Hall B1
• Abstract Number: 8500
• Citation: J Clin Oncol 36, 2018 (suppl; abstr 8500)
• Author(s): Greg Andrew Durm, Sandra K. Althouse, Ahad Ali Sadiq, Shadia Ibrahim Jalal, Salma Jabbour, Robin Zon, Goetz H. Kloecker, William B. Fisher, Karen L. Reckamp, Ebenezer A. Kio, Robert M. Langdon, Bamidele Adesunloye, Ryan D. Gentzler, Nasser H. Hanna; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Michiana Hematology Oncology, PC, South Bend, IN; University of Louisville School of Medicine, Department of Internal Medicine, Division of Hematology and Medical Oncology, James Brown Graham Cancer Center, Louisville, KY; Medical Consultants, Muncie, IN; City of Hope Comprehensive Cancer Center, Duarte, CA; Goshen Center for Cancer Care, Goshen, IN; Nebraska Cancer Spclsts, Omaha, NE; National Institutes of Health, Westfiled, IN; University of Virginia, Charlottesville, VA

Attending ASCO? Stop by the HCRN Booth (#25099) in McCormick Place South, Exhibit Hall A.

About Hoosier Cancer Research Network:

Hoosier Cancer Research Network (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has conducted more than 180 trials in a variety of cancer types and supportive care, resulting in more than 350 publications. More than 7,500 subjects have participated in Hoosier Cancer Research Network clinical trials.